Edwards Lifesciences (NYSE: EW) reported earnings on Oct. 19. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Edwards Lifesciences missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded significantly.

Margins expanded across the board.

Revenue details
 Edwards Lifesciences booked revenue of $448.0 million. The 20 analysts polled by S&P Capital IQ predicted revenue of $476.6 million on the same basis. GAAP reported sales were 8.5% higher than the prior-year quarter's $412.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.58. The 22 earnings estimates compiled by S&P Capital IQ averaged $0.56 per share. GAAP EPS of $0.58 for Q3 were 35% higher than the prior-year quarter's $0.43 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 75.1%, 550 basis points better than the prior-year quarter. Operating margin was 21.1%, 660 basis points better than the prior-year quarter. Net margin was 15.4%, 290 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $500.6 million. On the bottom line, the average EPS estimate is $0.80.

Next year's average estimate for revenue is $1.89 billion. The average EPS estimate is $2.57.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 147 members out of 202 rating the stock outperform, and 55 members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Edwards Lifesciences a green thumbs-up, and 22 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $104.37.